Active	Status	Sponsor type	Region	Phase	Filter
17 Active 6 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vernino, Steven
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy	Active, not recruiting	2	159	Europe, Japan, US	TAK-341, MEDI1341, Placebo	Takeda, AstraZeneca	Multiple System Atrophy	07/25	07/25
iSTAND, NCT03919773: IVIG (Gamunex-C) Treatment Study for POTS Subjects	Completed	1/2	30	US	IVIG, intravenous immunoglobulin, Albumin	University of Texas Southwestern Medical Center, Grifols Biologicals, LLC, Dysautonomia International	Postural Tachycardia Syndrome	06/23	12/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vernino, Steven
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy	Active, not recruiting	2	159	Europe, Japan, US	TAK-341, MEDI1341, Placebo	Takeda, AstraZeneca	Multiple System Atrophy	07/25	07/25
iSTAND, NCT03919773: IVIG (Gamunex-C) Treatment Study for POTS Subjects	Completed	1/2	30	US	IVIG, intravenous immunoglobulin, Albumin	University of Texas Southwestern Medical Center, Grifols Biologicals, LLC, Dysautonomia International	Postural Tachycardia Syndrome	06/23	12/23